Cargando…
A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG
BACKGROUND: HeberFERON is a co-formulation of α2b and γ interferons, based on their synergism, which has shown its clinical superiority over individual interferons in basal cell carcinomas. In glioblastoma (GBM), HeberFERON has displayed promising preclinical and clinical results. This led us to des...
Autores principales: | Miranda, Jamilet, Vázquez-Blomquist, Dania, Bringas, Ricardo, Fernandez-de-Cossio, Jorge, Palenzuela, Daniel, Novoa, Lidia I., Bello-Rivero, Iraldo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463508/ https://www.ncbi.nlm.nih.gov/pubmed/37644431 http://dx.doi.org/10.1186/s12885-023-11330-2 |
Ejemplares similares
-
Proteomics and Phospho-Proteomics Profiling of the Co-Formulation of Type I and II Interferons, HeberFERON, in the Glioblastoma-Derived Cell Line U-87 MG
por: Vázquez-Blomquist, Dania, et al.
Publicado: (2022) -
Exosome Proteome of U-87MG Glioblastoma Cells
por: Chun, Sohyun, et al.
Publicado: (2016) -
Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study
por: Anasagasti-Angulo, Lorenzo, et al.
Publicado: (2009) -
Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial
por: García-Vega, Yanelda, et al.
Publicado: (2012) -
Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
por: García-García, Idrian, et al.
Publicado: (2016)